2/10/26
CorestemChemon, a biopharmaceutical company headquartered in South Korea, has selected Winston-Salem as the location for its U.S. base of operations.
In South Korea, the company has successfully completed clinical trials for Neuronata-R, a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS), making it one of only a small number of stem cell therapies approved for use globally. From its U.S. base in Winston-Salem, CorestemChemon plans to advance its therapies through U.S. regulatory pathways while building research, clinical and business partnerships.
“Establishing our U.S. operations in Winston-Salem represents an important milestone in CorestemChemon’s global strategy,” said Seung Beom Yang, director of CorestemChemon. “The opportunity to work within the RegenMed Engine and alongside the Wake Forest Institute for Regenerative Medicine (WFIRM), the world’s leading translational regenerative medicine institution, provides a strong foundation for expanding our therapies into the U.S. market and increasing our impact for patients worldwide.”